Article Sidebar
Views PDF: 78
SURVIVAL RESULTS AND ASSOCIATED FACTORS OF BEP REGIMEN CHEMOTHERAPY IN METASTATIC TESTICULAR CANCER
Main Article Content
Abstract
Objective: Our study aimed to evaluated survival results and associated factors of BEP regimen chemotherapy in metastatic testicular cancer. Patients and method: Restropective and prospective description study of 36 patients with metastatic testicular cancer who received bleomycin, etoposide, and cisplatin chemotherapy at K hospital from 1/2014 to 6/2022. Results: The mean age of patients was 32.6 years old. Seminoma accounted for 33.3% and nonseminoma accounted for 66.7%. The most common metastatic was lung accounting for 38.9% respectively. Mean progression-free time and overall survival time were 67.6 months and 75.5 months, respectively. The disease-free and overall survival rates at 5 years were 66.7% and 77.8% respectively. Patients with a biochemical complete response and the intermediate-low risk subgroup had better progression-free and overall survival time compared to nonresponse on biochemistry, high-risk patients (p<0.05). Conclusion: The BEP regimen is highly effective, so it can be widely applied in clinical practice in the treatment of metastatic testicular cancer.
Article Details
Keywords
Testicular cancer, metastatic, BEP
References
2. Cấn Xuân Hạnh: Đánh giá kết quả điều trị ung thư tinh hoàn tại bệnh viện K từ 2005 đến 2013. 2014.
3. Hanna N. và Einhorn L.H. (2014). Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol, 32(28), 3085–3092.
4. De Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995;71(6):1311-1314.
5. Culine S, Kramar A, Théodore C, et al. Randomized Trial Comparing Bleomycin /Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. JCO. 2008;26(3):421-427.
6. Mead GM, Stenning SP. The international germ cell consensus classification: A new prognostic factor-based staging classification for metastatic germ cell tumours. Clinical Oncology. 1997;9(4):207-209.
7. De Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. JCO. 2001;19(6):1629-1640.
8. Grimison PS, Stockler MR, Thomson DB, et al. Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. JNCI: Journal of the National Cancer Institute. 2010;102(16):1253-1262.
9. Shiraishi T, Nakamura T, Ukimura O. Cancer Registration Committee of the Japanese Urological Association. Chemotherapy for metastatic testicular cancer: The first nationwide multi-institutional study by the Cancer Registration Committee of the Japanese Urological Association. Int J Urol. 2018;25:730-736.
10. Nakamura T, Ueda T, Oishi M, et al. Importance of Continuous Sequential Chemotherapy and Multimodal Treatment for Advanced Testicular Cancer: A High-Volume Japanese Center Experience. Medicine. 2015;94(11):e653.